Establishment of a primary renal lymphoma model and its clinical relevance

被引:5
作者
Li, Xiaoxi [1 ]
Deng, Minyao [1 ]
Zhang, Chenxiao [1 ]
Luo, Lingli [1 ]
Qian, Hui [1 ]
机构
[1] Jiangsu Univ, Sch Med, Dept Lab Med, Zhenjiang, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
primary renal lymphoma; extranodal lymphoma; extranodal dissemination; MA-K; MCD subtype; LymphGen; aggressive B-cell lymphoma; translation pathway; B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMAS; MONOCLONAL-ANTIBODY; RIBOSOME BIOGENESIS; DISTINCT TYPES; CLASSIFICATION; ALEMTUZUMAB; PROGRESSION; EXPRESSION; CAMPATH-1H;
D O I
10.3389/fonc.2023.1089187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Extranodal dissemination is an important feature of aggressive B-cell lymphoma. Owing to the lack of available animal models, the study on extranodal dissemination of lymphoma is greatly limited. Here, we identified a novel cell line, named MA-K, which originated from the E mu-Myc;Cdkn2a-/- cell line, named MA-LN in this study. Compared to MA-LN, MA-K tended to disseminate in the kidney rather than the lymph nodes in the lymphoma transplantation model, resembling human primary renal lymphoma. The transcriptome analysis revealed that MA-K had undergone transcriptional evolution during the culture. The specialized transcriptional pattern analysis we proposed in this study identified that the FOXO1-BTG1-MYD88 pattern was formed in MA-K. Further analysis found that the translation pathway was the most enriched pathway in specially expressed genes (SEGs) in MA-K. Among the SEGs, three upregulated genes, RPLP2, RPS16, and MRPS16, and five downregulated genes, SSPN, CD52, ANKRD37, CCDC82, and VPREB3, in MA-K were identified as promising biomarkers to predict the clinical outcomes of human DLBCL. Moreover, the joint expression of the five-gene signature could effectively predict clinical outcomes of human DLBCL in three groups. These findings suggested that the MA-K cell line had strong clinical relevance with human aggressive B-cell lymphoma. Moreover, the MA-K primary renal lymphoma model, as a novel syngenetic mouse model, will be greatly useful for both basic research on lymphoma dissemination and preclinical efficacy evaluation of chemotherapy and immunotherapy.
引用
收藏
页数:11
相关论文
共 38 条
[11]   Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges [J].
Day, Chi-Ping ;
Merlino, Glenn ;
Van Dyke, Terry .
CELL, 2015, 163 (01) :39-53
[12]   Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis [J].
Eischen, CM ;
Weber, JD ;
Roussel, MF ;
Sherr, CJ ;
Cleveland, JL .
GENES & DEVELOPMENT, 1999, 13 (20) :2658-2669
[13]   Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance [J].
Elhamamsy, Amr R. ;
Metge, Brandon J. ;
Alsheikh, Heba A. ;
Shevde, Lalita A. ;
Samant, Rajeev S. .
CANCER RESEARCH, 2022, 82 (13) :2344-2353
[14]   Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies [J].
Faderl, S ;
Thomas, DA ;
O'Brien, S ;
Garcia-Manero, G ;
Kantarjian, HM ;
Giles, FJ ;
Koller, C ;
Ferrajoli, A ;
Verstovsek, S ;
Pro, B ;
Andreeff, M ;
Beran, M ;
Cortes, J ;
Wierda, W ;
Tran, N ;
Keating, MJ .
BLOOD, 2003, 101 (09) :3413-3415
[15]   Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells [J].
Ferrao, P. T. ;
Bukczynska, E. P. ;
Johnstone, R. W. ;
McArthur, G. A. .
ONCOGENE, 2012, 31 (13) :1661-1672
[16]   Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL [J].
Geisler, Christian H. ;
vant' Veer, Mars B. ;
Jurlander, Jesper ;
Walewski, Jan ;
Tjonnfjord, Geir ;
Remes, Maija Itala ;
Kimby, Eva ;
Kozak, Tomas ;
Polliack, Aaron ;
Wu, Ka Lung ;
Wittebol, Shulamiet ;
Abrahamse-Testroote, Martine C. J. ;
Doorduijn, Jeanette ;
Alemayehu, Wendimagegn Ghidey ;
van Oers, Marinus H. J. .
BLOOD, 2014, 123 (21) :3255-3262
[17]   MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma [J].
Hattori, Keiichiro ;
Sakata-Yanagimoto, Mamiko ;
Okoshi, Yasushi ;
Goshima, Yuki ;
Yanagimoto, Shintaro ;
Nakamoto-Matsubara, Rie ;
Sato, Taiki ;
Noguchi, Masayuki ;
Takano, Shingo ;
Ishikawa, Eichi ;
Yamamoto, Tetsuya ;
Matsumura, Akira ;
Chiba, Shigeru .
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (03) :492-494
[18]   High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma [J].
Kraan, W. ;
van Keimpema, M. ;
Horlings, H. M. ;
Schilder-Tol, E. J. M. ;
Oud, M. E. C. M. ;
Noorduyn, L. A. ;
Kluin, P. M. ;
Kersten, M. J. ;
Spaargaren, M. ;
Pals, S. T. .
LEUKEMIA, 2014, 28 (03) :719-720
[19]   Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene [J].
Lefebure, Marcus ;
Tothill, Richard W. ;
Kruse, Elizabeth ;
Hawkins, Edwin D. ;
Shortt, Jake ;
Matthews, Geoffrey M. ;
Gregory, Gareth P. ;
Martin, Benjamin P. ;
Kelly, Madison J. ;
Todorovski, Izabela ;
Doyle, Maria A. ;
Lupat, Richard ;
Li, Jason ;
Schroeder, Jan ;
Wall, Meaghan ;
Craig, Stuart ;
Poortinga, Gretchen ;
Cameron, Don ;
Bywater, Megan ;
Kats, Lev ;
Gearhart, Micah D. ;
Bardwell, Vivian J. ;
Dickins, Ross A. ;
Hannan, Ross D. ;
Papenfuss, Anthony T. ;
Johnstone, Ricky W. .
NATURE COMMUNICATIONS, 2017, 8 :1-10
[20]   Stromal Gene Signatures in Large-B-Cell Lymphomas [J].
Lenz, G. ;
Wright, G. ;
Dave, S. S. ;
Xiao, W. ;
Powell, J. ;
Zhao, H. ;
Xu, W. ;
Tan, B. ;
Goldschmidt, N. ;
Iqbal, J. ;
Vose, J. ;
Bast, M. ;
Fu, K. ;
Weisenburger, D. D. ;
Greiner, T. C. ;
Armitage, J. O. ;
Kyle, A. ;
May, L. ;
Gascoyne, R. D. ;
Connors, J. M. ;
Troen, G. ;
Holte, H. ;
Kvaloy, S. ;
Dierickx, D. ;
Verhoef, G. ;
Delabie, J. ;
Smeland, E. B. ;
Jares, P. ;
Martinez, A. ;
Lopez-Guillermo, A. ;
Montserrat, E. ;
Campo, E. ;
Braziel, R. M. ;
Miller, T. P. ;
Rimsza, L. M. ;
Cook, J. R. ;
Pohlman, B. ;
Sweetenham, J. ;
Tubbs, R. R. ;
Fisher, R. I. ;
Hartmann, E. ;
Rosenwald, A. ;
Ott, G. ;
Muller-Hermelink, H. -K ;
Wrench, D. ;
Lister, T. A. ;
Jaffe, E. S. ;
Wilson, W. H. ;
Chan, W. C. ;
Staudt, L. M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (22) :2313-2323